Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Maridebart Cafraglutide

MARITIME-1

Amgen · Phase 3 · Active, not recruiting · Enrollment 3853

NCT06858839

Participants reaching a weight loss threshold

Participants reaching threshold, %

Source: Cited trial source. The denominator is the source figure, when it states one.

No selected arm reports a responder percent.

Show as table
Arm≥5%≥10%≥15%≥20%
Maridebart Cafraglutide High Dosen/rn/rn/rn/r
Maridebart Cafraglutide Medium Dosen/rn/rn/rn/r
Maridebart Cafraglutide Low Dosen/rn/rn/rn/r
Placebon/rn/rn/rn/r

Not shown

  • Maridebart Cafraglutide High Dose: endpoint not reported
  • Maridebart Cafraglutide Medium Dose: endpoint not reported
  • Maridebart Cafraglutide Low Dose: endpoint not reported
  • Placebo: endpoint not reported